CA-50 serum level in patients with prostate cancer.
CA-50 antigen is considered to be a generalized carcinoma-associated antigen. CA-50 serum levels were measured by solid phase radioimmunoassay using a specific monoclonal antibody. Sera of 49 patients with prostatic cancer of different clinical stages, 43 patients suffering from BPH, and 28 healthy males were tested. Positive test results were observed in 57.1% of patients with prostate cancer values ranging from 42.9% in stage A to 66.7% in stage D. Increased CA-50 levels were found in 11.6% of patients with BPH.
Marczyńska
A
A
Department of Clinical Biochemistry, Oncology Center, Cracow, Poland.
Kulpa
J
J
Leńko
J
J
Bugajski
A
A
Wójcik
E
E
D000368:Aged; D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis*; D011863:Radioimmunoassay
D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor